These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 15701885)

  • 1. TAS-108: a novel steroidal antiestrogen.
    Buzdar AU
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):906s-8s. PubMed ID: 15701885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer.
    Blakely LJ; Buzdar A; Chang HY; Frye D; Theriault R; Valero V; Rivera E; Booser D; Kuritani J; Tsuda M
    Clin Cancer Res; 2004 Aug; 10(16):5425-31. PubMed ID: 15328180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fulvestrant].
    Roth S; Schaad S; Hardel V; Jaehde U
    Dtsch Med Wochenschr; 2006 Dec; 131(48):2718-21. PubMed ID: 17123238
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety, tolerability and pharmacokinetics of TAS-108, a novel anti-oestrogen, in healthy post-menopausal Japanese women: a phase I single oral dose study.
    Kumagai Y; Fujita T; Ozaki M; Yokota S; Maeda M; Shida M; Otani Y; Yamaya H; Tsuruta H
    Basic Clin Pharmacol Toxicol; 2009 May; 104(5):352-9. PubMed ID: 19175362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and II studies of toremifene.
    Hamm JT
    Oncology (Williston Park); 1997 May; 11(5 Suppl 4):19-22. PubMed ID: 9165502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668.
    Fog CK; Christensen IJ; Lykkesfeldt AE
    Breast Cancer Res Treat; 2005 May; 91(2):133-44. PubMed ID: 15868441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose.
    Yamaya H; Yoshida K; Kuritani J; Yonezawa J; Tsuda M; Shindo T; Nagayama S; Buzdar AU
    J Clin Pharm Ther; 2005 Oct; 30(5):459-70. PubMed ID: 16164493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pure oestrogen antagonists for the treatment of advanced breast cancer.
    Howell A
    Endocr Relat Cancer; 2006 Sep; 13(3):689-706. PubMed ID: 16954425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clusterin: a potential target for improving response to antiestrogens.
    Toffanin S; Daidone MG; Miodini P; De Cecco L; Gandellini P; Cappelletti V
    Int J Oncol; 2008 Oct; 33(4):791-8. PubMed ID: 18813793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines.
    Vendrell JA; Bieche I; Desmetz C; Badia E; Tozlu S; Nguyen C; Nicolas JC; Lidereau R; Cohen PA
    Endocr Relat Cancer; 2005 Mar; 12(1):75-92. PubMed ID: 15788640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T; Rustum Y; Levine E; Creaven P
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
    Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
    Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J; Sommer A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells.
    Yde CW; Clausen MP; Bennetzen MV; Lykkesfeldt AE; Mouritsen OG; Guerra B
    Anticancer Drugs; 2009 Sep; 20(8):723-35. PubMed ID: 19584708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer.
    Saeki T; Noguchi S; Aogi K; Inaji H; Tabei T; Ikeda T
    Ann Oncol; 2009 May; 20(5):868-73. PubMed ID: 19150935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
    Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
    Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
    Van Poznak CH; Hayes DF
    J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
    [No Abstract]   [Full Text] [Related]  

  • 19. Fulvestrant: spreading the word, but not too thinly.
    Wilcken NR; Stockler MR
    Lancet; 2003 Oct; 362(9392):1254. PubMed ID: 14575967
    [No Abstract]   [Full Text] [Related]  

  • 20. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy.
    Rahko E; Jukkola A; Melkko J; Paavo P; Bloigu R; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
    Anticancer Res; 2004; 24(6):4247-53. PubMed ID: 15736480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.